Overview

Akiram Therapeutics is a Swedish biotech company committed to developing innovative and targeted molecular radiotherapy for patients with incurable cancer. Our product combines a radiation component with a proprietary antibody to deliver radioactivity directly to cancer cells while minimizing damage to surrounding healthy tissues. Our research is based on cutting-edge discoveries made at Uppsala University, and our team is composed of experts in radiation sciences, cancer precision medicine, and drug development. At Akiram, our mission is to make targeted molecular radiotherapy widely accessible to cancer patients. We recognize that each patient's cancer is unique and requires a personalized approach to treatment. By utilizing state-of-the-art radiopharmaceuticals and precision medicine, we aim to create more effective and personalized treatments for people fighting cancer.